Local and systemic tolerability of a 2'O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey

• Published in: Inhalation toxicology Vol. 26; no. 8; p. 452
• Main Authors: Fey, Robert A, Templin, Michael V, McDonald, Jacob D, Yu, Rosie Z, Hutt, Julie A, Gigliotti, Andrew P, Henry, Scott P, Reed, Matthew D
• Format: Journal Article
• Language: English
• Published: England 01.07.2014
• Subjects: Animals; Female; Lung - drug effects; Lung - metabolism; Lung - pathology; Lung - physiology; Macaca; Male; Mice; Oligonucleotides - blood; Oligonucleotides - pharmacokinetics; Oligonucleotides - toxicity; Oligonucleotides, Antisense - blood; Oligonucleotides, Antisense - pharmacokinetics; Oligonucleotides, Antisense - toxicity; Receptors, Cell Surface - genetics; RNA, Messenger - metabolism; inhalation; mouse; aerosolization; antisense oligonucleotides; interleukin 4 receptor-α; non-human primates; asthma
• ISSN: 1091-7691
• DOI: 10.3109/08958378.2014.907587

Antisense oligonucleotides (ASOs) bind and facilitate degradation of RNA and inhibit protein expression in pathways not easily targeted with small molecules or antibodies. Interleukin (IL)-4 and IL-13 potentiate signaling through the shared IL-4 receptor-α (IL-4Rα) subunit of their receptors. ASO targeting of IL-4Rα mRNA in a mouse model of asthma led to attenuation of airway hyperactivity, demonstrating potential benefit in asthma patients. This study focused on tolerability of inhaled IL-4Rα-targeting ASOs. Toxicity studies were performed with mouse- (ISIS 23189) and human-specific (ISIS 369645) sequences administered by inhalation. Four week (monkey) or 13 week (mouse) repeat doses at levels of up to 15 mg/kg/exposure (exp) and 50 mg/kg/exp, respectively, demonstrated dose-dependent effects limited to increases in macrophage size and number in lung and tracheobronchial lymph nodes. The changes were largely non-specific, reflecting adaptive responses that occur during active exposure and deposition of ASO and other material in the lung. Reversibility was observed at a rate consistent with the kinetics of tissue clearance of ASO. Systemic bioavailability was minimal, and no systemic toxicity was observed at exposure levels appreciably above pharmacological doses and doses proposed for clinical trials.